[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cocaine-dependence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cocaine-dependence":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,53,85,113,145,171],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100514108","rtms-and-cognitive-behavioral-therapy-for-cocaine-use-disorder-100514108",false,"NCT05974202","rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder","Augmenting Cognitive-behavioral Therapy With rTMS of the Medial Prefrontal and Anterior Cingulate Cortices for the Treatment of Cocaine Use Disorder","Inclusion Criteria:\n\n1. Age 22-65;\n2. Able to give informed consent and comply with study procedures;\n3. Meets DSM-5 criteria for current moderate\u002Fsevere CUD and are treatment-seeking;\n4. Used cocaine at least 9 days in the past 28 days, with at least weekly cocaine use;\n5. Agree to no more than moderate alcohol consumption (\\\u003C15 drinks\u002Fweek for men and \\\u003C8 drinks\u002Fweek for women) and to avoid using amphetamine\u002Fmethamphetamine and non-prescribed benzodiazepines or barbiturates; and\n6. Women of childbearing potential must agree to use a method of contraception with proven efficacy and agree to not become pregnant during the study.\n\nExclusion Criteria:\n\n1. Meets DSM-5 criteria for current moderate\u002Fsevere major depressive episode, OCD, bipolar disorder, schizophrenia or any psychotic disorder other than transient psychosis due to substance use;\n2. Hamilton Depression Rating Scale score \\> 17;\n3. Young Mania Rating Scale score \\>10;\n4. Meets DSM-5 criteria for current moderate\u002Fsevere other substance use disorder (aside from tobacco use disorder; physiologic dependence on any other substance other than nicotine, including alcohol, is exclusionary);\n5. Heavy weekly alcohol drinking as defined by an average of \\>14 drinks\u002Fweek for men or \\>7 drinks\u002Fweek for women on average during the past 28 days;\n6. Prior alcohol, benzodiazepine, or barbiturate withdrawal that resulted in hospitalization, medical detoxification, or resulted in seizures or delirium tremens;\n7. More than twice weekly use of non-prescribed medications\u002Fdrugs that may change the seizure threshold, including benzodiazepines, barbiturates, GHB\u002FGBL, amphetamines\u002Fmethamphetamine;\n8. Any other current DSM-5 psychiatric disorder(s) that in the investigator's judgment are unstable, would be disrupted by study procedures, or are likely to require pharmacotherapy or psychotherapy during the study period;\n9. Significant current suicide risk, indicated by either: (1) \"yes\" response on #3, 4, or #5 on the C-SSRS and a psychiatric risk assessment indicating a moderate or high risk of suicide or (2) suicidal behavior in the past 3 months (note: non-suicidal self-injurious behavior is not exclusionary);\n10. Females with a positive urine pregnancy test;\n11. Clinically significant abnormal cardiac functioning per electrocardiogram (ECG) (required for any participant age 60 years and older);\n12. Seizure history including: seizure disorder\u002Fepilepsy, alcohol\u002Fdrug withdrawal seizure, or seizure deemed by the study physician to be related to cocaine intoxication\u002Fwithdrawal (note: febrile seizures are not exclusionary)\n13. Other medical conditions that are relatively contraindicated with TMS (seizure disorders, glaucoma, increased intracranial pressure, severe migraines, stroke, brain lesions, pregnancy or breast-feeding, neurodegenerative disease, meningoencephalitis, intracerebral abscess, parenchymal or leptomeningeal cancers);\n14. Medications that lower seizure threshold and in the opinion of the investigator impose significant seizure risk for the individual (including bupropion, antipsychotics, lithium, anticholinergics, and tricyclic antidepressants);\n15. Cognitive disorder (MMSE \\\u003C25);\n16. Disqualifying response on the TMS Adult Safety Screen (TASS);\n17. Implanted devices or stimulators (cardiac pacemakers, vagus nerve stimulators, spinal cord stimulators, cochlear implant);\n18. Currently taking ototoxic medications (aminoglycosides, cisplatin);\n19. Metal implants or paramagnetic objects in the body that prohibits MR scanning;\n20. Claustrophobia that prohibits MR scanning; or\n21. Legally mandated (e.g., to avoid incarceration or other penalties) to participate in SUD treatment program.","ALL","22 Years","65 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to compare the effects of active repetitive transcranial magnetic stimulation (rTMS) to sham (placebo) rTMS prior to cognitive-behavioral therapy (CBT) as a treatment for adults with cocaine use disorder. The main questions it aims to answer are:\n\n* Is rTMS safe and feasible as an augmentation for CBT for the treatment of cocaine use disorder?\n* What is the brain mechanism of rTMS?\n* Will active rTMS (compared to sham rTMS) followed by CBT help adults with cocaine use disorder achieve abstinence from cocaine?\n\nParticipants will:\n\n* Have two brain MRI scans;\n* Undergo 3 weeks of daily rTMS (or sham) treatments (15 sessions), and;\n* Have 12 weeks of once-weekly cognitive-behavioral therapy for the treatment of cocaine use disorder.\n\nResearchers will compare active (real) rTMS to sham (placebo) rTMS. All participants will receive cognitive-behavioral therapy.\n\nThe former principle investigator, Dr. Derek Blevins, has vacated his position (February 2025), and has transferred the principle investigator role to Dr. John Mariani, the STARS Clinic Director.",[27,28,29,30,31],"Cocaine Use","Cocaine Dependence","Cocaine Use Disorder","Cocaine Use Disorder, Moderate","Cocaine Use Disorder, Severe",[33,34,35,36,37,38,39],"Repetitive transcranial magnetic stimulation","rTMS","TMS","Cognitive behavioral therapy","CBT","Functional magnetic resonance imaging","fMRI","NOT_YET_RECRUITING","2026-04-06",{"date":43,"type":44},"2026-04-07","ACTUAL",{"date":46,"type":21},"2026-05-01",{"date":48,"type":21},"2028-04-28",{"name":50,"class":51},"New York State Psychiatric Institute","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":52},"100617427","transcranial-direct-current-stimulation-tdcs-for-treatment-of-cocaine-use-disorder-100617427","NCT07318480","Transcranial Direct Current Stimulation (tDCS) for Treatment of Cocaine Use Disorder","Cognitively-enhanced tDCS of the Dorsolateral Prefrontal Cortex to Reduce Craving in Cocaine Addiction","Inclusion Criteria:\n\n* Ability to understand and give informed consent\n* Men and women 18-60 years of age.\n* For women of childbearing potential, current use of a medically acceptable form of birth control\n* DSM-5 diagnosis of stimulant use disorder with crack\u002Fcocaine as the drug of choice\n\nExclusion Criteria:\n\n* Lifetime diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar I disorder, or delusional disorder as confirmed by the MINI or autism spectrum disorder as confirmed by medical history at the screening visit\n* Current clinically significant or unstable medical conditions, including metabolic, endocrinological, oncological or autoimmune diseases, infectious diseases common in people with substance use disorders including Hepatitis B and C or HIV\u002FAIDS; use of medications deemed exclusionary by the study team; or any laboratory value outside the reference range that the senior investigator team considers to be of clinical relevance\n* Head trauma with loss of consciousness (\\>30 min)\n* History of neurological or developmental disease of central origin including stroke, brain tumor or seizures, encompassing those symptoms associated with periods of drug withdrawal or abstinence\n* Metal implants or devices that may be impacted by the electrical stimulation and additional MR contraindications\n* Women of childbearing potential must use a medically acceptable birth control method during the study and will be asked to take a pregnancy urine test before exposure to tDCS (or MRI)","18 Years","60 Years",{"count":63,"type":21},120,[24],"The researchers will test whether cognitively enhanced transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex can reduce craving in inpatients with cocaine use disorder. Neuroimaging before and after stimulation will establish the neural correlates of recovery and allow predictions of outcomes, which will be assessed throughout the study and one month after its completion. Results could pave the way towards development of a new self-administered intervention to reduce craving when it is needed the most, enhancing recovery real-time and in the natural environment in people with cocaine addiction as generalizable to other drugs of abuse and other disorders of self-control.",[29,28,67],"Substance Use Disorder (SUD)",[69,70,71,72,73,74],"Transcranial Direct Current Stimulation (tDCS)","Brain Stimulation","cocaine use disorder","drug craving","neuromodulation","neuroimaging","RECRUITING","2026-03-02",{"date":78,"type":44},"2026-03-03",{"date":80,"type":44},"2026-02-25",{"date":82,"type":21},"2030-02",{"name":84,"class":51},"Icahn School of Medicine at Mount Sinai",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":98,"conditions":99,"keywords":100,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":52},"100244061","phase-1-safety-study-of-a-disrupted-adenovirus-ad-serotype-cocaine-vaccine-for-cocaine-dependent-individuals-100244061","NCT02455479","Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals","Phase I Randomized, Double-blind, Placebo Control Study for an Anti-cocaine Vaccine","Accrual will be random, with no bias as to gender or racial\u002Fethnic group. Because the accrual process will be random, it is possible that there may be differences in the proportion of males and females, and racial\u002Fethnic groups among the study individuals. All subjects will be concurrently participating in behavioral therapy programs run by Dr. Beeder's clinical team. Each case will be reviewed with the Eligibility Committee, comprised of three investigators other than the PI, to determine eligibility. The Principal Investigator will not participate in this process.\n\nAll subjects must fulfill all inclusion criteria and none of the exclusion criteria in order to participate in this study.\n\nInclusion Criteria:\n\n1. All subjects should be able to provide informed consent.\n2. Must provide HIV informed consent.\n3. Males and females, 21- 69 years of age.\n4. Individuals that have been diagnosed with a cocaine use disorder according to DSM-V-TR criteria, with documented evidence of cocaine use within the past 60 days and have previously used an average of 1 to 10 grams of powdered and\u002For crack cocaine (via insufflation or smoking only) per week. Any prior 1 to 4 month period of cocaine abstinence in the past year will be excluded when calculating average cocaine use to evaluate study eligibility.\n\n6\\. Fertile males and females must agree to use adequate forms of contraception for the duration of the entire study.\n\n7\\. Body weight \\> 45 kg.\n\nExclusion Criteria:\n\n1. Individuals not deemed in good overall health by the investigator.\n2. Diagnosed history of severe psychotic disorders.\n3. Abnormal EKG at screening with changes consistent with cardiac disease.\n4. History of significant cardiovascular disease, hypertension, prior myocardial infarction and\u002For cerebrovascular event.\n5. Individuals who are currently on beta-blockers.\n6. Physical signs or laboratory values suggestive of systemic disorders.\n7. History of attempted suicide, as assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) and\u002For committed homicide.\n8. History of diagnosed obsessive compulsive disorder (OCD).\n9. Known allergy to soy.\n10. Individuals who are currently taking alprazolam (Xanax) or ziprasidone (Geodon).\n11. Evidence of active infection of any types, including COVID-19, or positive for human immunodeficiency virus (HIV).\n12. Historical or current use of immunomodulators or immunosuppressants \\\u003C5 years prior to screening.\n13. Receipt of blood within 3 months of screening.\n14. Females who are pregnant or nursing.\n15. Concurrent participation in any other FDA approved Investigational New Drug.\n16. Abnormal liver function (transaminases greater than 2x the upper limit of normal values)\n17. eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2\n18. Severe substance use disorder based on DSM-V-TR criteria (excluding cocaine, nicotine, caffeine, alcohol, marijuana and opiates prescribed for medication assisted therapy or pain treatment) currently not in remission according to one of the following criteria:\n\n    * Early Full Remission: This specifier is used if none of the criteria for Dependence or Abuse have been met for at least 1 month, but less than 12 months OR\n    * Early Partial Remission: This specifier is used if only one or more (but not all) of the criteria for Dependence or Abuse has\u002Fhave been met for at least 1 month, but less than 12 months. OR\n    * Sustained Full Remission: This specifier is used if none of the criteria for Dependence or Abuse have been met at any time during a period of 12 months or longer OR\n    * Sustained Partial Remission: This specifier is used if only one or more (but not all) of the criteria for Dependence or Abuse has\u002Fhave been met for a period of 12 months or longer OR\n    * On Agonist Therapy: This specifier is used if the individual is on a prescribed agonist medication, and none of the criteria for Dependence or Abuse has been met for that class of medication for at least the past month (except tolerance to, or withdrawal from, the agonist). This category also applies to those being treated for Dependence using a partial agonist or an agonist\u002Fantagonist OR\n    * Substance Use Related Disorder (mild) up to two disorders: Patients that are assessed to have mild substance-use-related disorders according to the DSM-V criteria will be allowed to participate in the study as long as the number of the disorder-resulting substances does not exceed two (with the exception of the nicotine, caffeine, alcohol, marijuana and opiates prescribed for medication assisted therapy or pain treatment).\n19. History of any seizure disorder.\n20. Individuals with history of Guillain-Barré Syndrome.\n21. Diagnosis of \\>2 Substance Use Related Disorders (mild) based on DSM-V- TR criteria (excluding nicotine, caffeine, alcohol, marijuana and opiates prescribed for medication assisted therapy or pain treatment\n22. On a prescribed agonist medication, with criteria for dependence or abuse for that class ofmedication for at least the past month (except tolerance to, or withdrawal from, the agonist","21 Years","69 Years",{"count":95,"type":21},150,[97],"PHASE1","The purpose of this study is to assess the safety and preliminary efficacy of an anti-cocaine vaccine called dAd5GNE in cocaine-dependent individuals. It uses the concept of a vaccine to treat the neurological effects of cocaine by evoking \"immunity\" to prevent the effects of cocaine on the brain.",[28],[101,102,103],"cocaine vaccine","cocaine dependence","Cocaine","2025-10-21",{"date":106,"type":44},"2025-10-23",{"date":108,"type":44},"2012-06-26",{"date":110,"type":21},"2027-12",{"name":112,"class":51},"Weill Medical College of Cornell University",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":125,"conditions":126,"keywords":127,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":52},"100525693","phase-2-ketamine-and-neurofeedback-training-effects-on-neuroplasticity-in-cocaine-addiction-100525693","NCT06125054","Ketamine and Neurofeedback-Training: Effects on Neuroplasticity in Cocaine Addiction","Boosting and Guiding Neuroplasticity by Combining Ketamine with Neurofeedback-assisted Learning - Towards an Individualized and Integrated Pharmaco-psychotherapy for Cocaine Addiction","Co-Boost","Inclusion Criteria:\n\n* Informed Consent as documented by signature\n* Male and female cocaine users 18 to 55 years of age\n* diagnostic and statisical manual (DSM)-5 diagnosis of CUD\n* Willingness to comply with the study protocol as explained by investigator\n* Normal level of language comprehension (German or Swiss-German)\n\nExclusion Criteria:\n\n* Current or lifetime psychotic disorders\n* History of severe substance-induced psychosis\n* Current or lifetime bipolar I or II disorders\n* Current suicidality\n* Previous suicide attempts during the last 2 years\n* Current severe alcohol use disorder\n* Current severe cannabis use disorder\n* Current moderate or severe stimulant use disorder (other than cocaine)\n* Current moderate or severe benzodiazepine use disorder\n* Current opioid use disorder\n* First-degree relatives with psychotic disorders\n* Beck Depression Inventory Score greater than 25\n* Unmedicated or unstable hypertension\n* Severe illness (e. g. myocardial ischemia or arrythmias, severe pulmonary secretions, glaucoma, congestive heart failure or angina, significant renal or hepatic impairment)\n* Acute infection (e. g. pulmonary or upper respiratory tract infection)\n* Insufficient treated or uncorrected hyperthyroidism\n* Severe central nervous system related traumas or disorders (e. g. stroke, cerebral trauma with loss of consciousness over more than 24h, epilepsy)\n* Increased intracranial pressure\n* Medication directly affecting glutamate signaling (e. g. anticonvulsant medication)\n* Any unstable psychoactive medication (no changes in compounds within last 4 weeks before start of study)\n* Pregnancy or lactation\n* Women of childbearing potential with no use of medically accepted contraceptive (e. g.\n\ncondoms, contraceptive diaphragm, birth control pill, hormone injection, intrauterine device)\n\n* BMI\\>35\n* Allergy, hypersensitivity, or other adverse reaction to previous use of ketamine\n* Contradictions to magnetic resonance imaging\n* Concurrent participation in other clinical study","55 Years",{"count":63,"type":21},[124],"PHASE2","The goal of this clinical trial is to learn about the effects of the combination of ketamine and realtime functional magnetic resonance imaging (fMRI) neurofeedback training in individuals with cocaine use disorder. The main questions the investigators aim to answer are:\n\n* Can the investigators observe a positive, significant effect on percentage of cocaine use days of both interventions combined as well as stand alone interventions?\n* Is there a significant transfer effect of the neurofeedback training?\n* Is there a significant, ketamine-dependent change in glutamate levels in the nucleus accumbens?\n\nParticipants will be given ketamine and a realtime fMRI neurofeedback training. Both interventions are placebo-controlled. The investigators will compare the four intervention groups to investigate the effects of the stand-alone effects of the intervention and the combination of it.",[29,28],[103,27,128,129,130,131,132,133,134,135],"Ketamine","Reward Sensitivity","Glutamate","Placebo-controlled","Therapeutic effects","Mechanistic effects","Neurofeedback Training","realtime fMRI","2024-12-17",{"date":138,"type":44},"2024-12-20",{"date":140,"type":44},"2024-02-05",{"date":142,"type":21},"2026-03",{"name":144,"class":51},"Dr. med. Marcus Herdener",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":158,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":52},"100530661","effect-of-hf-rtms-on-serum-bdnf-in-cocaine-use-disorder-100530661","NCT06189690","Effect of HF rTMS on Serum BDNF in Cocaine Use Disorder","Effects of 5-Hz Repetitive Transcranial Magnetic Stimulation on Serum Brain Derived Neurotrophic Factor and Clinical Variables in Cocaine Use Disorder","Inclusion Criteria:\n\n1. Current cocaine use disorder according to the Diagnostic and statistical manual of mental disorders (DSM 5).\n2. Cocaine crack or powder use for at least 12 months with a frequency of 3 times or more per week, with abstinence periods shorter than 1 year for the last year.\n3. Primary school completed.\n\nExclusion Criteria:\n\n1. Personal or first degree family history of any neurological disorder including, but not limited to, organic brain syndrome, epilepsy, brain injuries, multiple sclerosis, conditions that increase intracranial pressure.\n2. Personal history of brain surgery or traumatic brain injury.\n3. Comorbilities that could represent a risk of neuroinfection or increased convulsive threshoid.\n4. Other than alcohol, tobacco or marijuana substance use disorder.\n5. If the patient does not meet the safety criteria for rTMS.\n6. Current use of any medication that might provoque seizures or any anticonvulsant drugs.\n7. Personal history of schizophrenia, mania\u002Fhypomania or OCD.\n8. Personal history of myocardial infarction, angina, congestive heart failure, cerebrovascular events, transient ischemic attack or any other heart condition currently undergoing medical treatment.\n9. Personal history of seizures or detection of paroxysmal EEG activity.","50 Years",{"count":154,"type":21},102,[24],"This study aims to explore the effect of 5-Hz rTMS over the left dorsolateral prefrontal cortex on the BDNF, craving and cognitive function. This study will be longitudinal, with a short-term double-blind placebo-controlled phase consisting of 20 rTMS sessions and a long-term phase, consisting of 2 weekly sessions for 12 weeks. Participants will be clinically assessed pre-treatment (T0), after 20-sessions phase (T1) and after 12-weeks phase (T2) by an interview about psychiatric symptoms. Also, blood will be obtained in the same T0, T1 and T2 to peripheral levels of BDNF determination. Cognitive state will be measured at the same time-points (T0, T1, T2) by paper-pencil and computerized neuropsychological assessment. Researchers will compare active rTMS versus placebo 5 Hz-rTMS on described variables. Additionally, a comparative group (without rTMS intervention) will be included to equivalently measure described variables during periods without cocaine consumption.",[28],[159,160,34,161],"Craving","BDNF","DLPFC","2023-12-19",{"date":164,"type":44},"2024-01-03",{"date":166,"type":44},"2022-01-06",{"date":168,"type":21},"2027-12-01",{"name":170,"class":51},"Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":61,"enrollmentInfo":178,"targetDuration":4,"studyType":180,"phases":4,"briefSummary":181,"conditions":182,"keywords":187,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":52},"100090609","substance-abuse-pre-treatment-screening-study-100090609","NCT00439049","Substance Abuse Pre-Treatment Screening Study","General Evaluation of Eligibility for Substance Abuse\u002FDependence Research","Inclusion Criteria:\n\n* Willing and able to participate in 3- to 6-month treatment program.\n* At least 18 years of age.\n* Seeking treatment for substances of abuse including (cocaine, opiates, and alcohol).\n* Generally physically healthy.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Mandated by the courts\u002Fparole officers to attend treatment.\n* Not seeking treatment for substances of abuse.\n* Plans to move from the Houston area within the 3- to 6-month treatment period.\n* Seeking treatment for a substance for which the Treatment Research Clinic (TRC) has no current trial.",{"count":179,"type":21},7500,"OBSERVATIONAL","The overarching goal of this project is to have a consolidated consent and evaluation procedure that will lead potential subjects to the most appropriate clinical trial or human laboratory study (and its consent process) for their presenting concerns or interests. A second purpose is to have a consolidated intake data base on which secondary analyses can be conducted.",[183,28,184,185,186],"Cocaine Abuse","Opiate Dependence","Alcohol Dependence","Substance Abuse",[186,188,189],"Treatment","Eligibility",{"date":191,"type":44},"2023-12-20",{"date":193,"type":4},"2005-10",{"date":195,"type":21},"2026-06",{"name":197,"class":51},"The University of Texas Health Science Center, Houston"]